Over the past decade, immune checkpoint blockade (ICB) therapy has revolutionized the
outlook for oncology with significant and sustained improvement in the overall patient …

Immune checkpoint inhibitor therapy has revolutionized the field of cancer immunotherapy.
Even though it has shown a durable response in some solid tumors, several patients do not …

Immune checkpoint inhibitors (ICPis) are emerging as the new corner stone of cancer
treatment due to their ability to produce durable responses in patients with various cancers …

Immune checkpoint blockade therapies (ICBs) are a prominent breakthrough in cancer
immunotherapy in recent years (named the 2013 “Breakthrough of the Year” by the Science …

Immune checkpoint inhibitors have transformed cancer therapy, but their optimal use is still
constrained by lack of response and toxicity. Biomarkers of response may facilitate drug …

Purpose of review Immune checkpoint inhibitors have revolutionised the treatment of
multiple malignancies and have a growing list of indications. As our familiarity with these …

Abstract Immune-checkpoint blockade (ICB), in particular PD-1 inhibition, has rapidly
changed the treatment landscape and altered therapeutic paradigms across many tumor …

Background The discovery of immune checkpoint proteins and the mechanisms by which
cancer cells utilize them to evade the immune system has transformed our approach to …

Checkpoint blockade-based immunotherapy offers new options and powerful weapons for
the treatment of cancer, but its efficacy varies greatly among different types of cancer and …

Cancer immunotherapy using immune-checkpoint blockade (ICB) has created a paradigm
shift in the treatment of advanced-stage cancers. The promising antitumour activity of …